SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious latent viral infectious diseases, today announced that it will make an oral presentation on April 24, 2024, at CRISPRMED24, the first CRISPR Medicine Conference, which is being held from April 23-25 in Copenhagen, Denmark. The presentation will highlight new data from the Company’s emerging preclinical program for herpes simplex virus-1 keratitis (HSV-1 Keratitis).
Presentation details:
Title: CRISPR/Cas9-mediated gene editing delivered by a single AAV vector inhibits viral reactivation of HSV-1 in a latent rabbit keratitis model
Session Title: Pre-clinical/Clinical Trials II
Abstract: 81
Presenter: Kevin Luk, Excision BioTherapeutics
Location: Ballroom 3
Date/Time: April 24, 2024, 16:45 to 18:25 pm (CEST)
About Excision BioTherapeutics, Inc.
Excision BioTherapeutics, Inc. develops CRISPR-based medicines as potential cures for serious latent viral infectious diseases based on its proprietary multiplexed gene editing platform that unites next-generation CRISPR nucleases with a novel gene editing approach to develop curative therapies. The Company’s pipeline targets large, underserved markets including herpes simplex virus-1 keratitis (HSV-1 keratitis), hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1). Excision’s foundational technologies were developed in the laboratories of Dr. Kamel Khalili at Temple University and Dr. Jennifer Doudna at the University of California, Berkeley. For more information, please visit www.excision.bio.
Contact:
John Fraunces
LifeSci Advisors
917-355-2395
jfraunces@lifesciadvisors.com
NEW YORK, Aug. 12, 2025 /PRNewswire/ -- HopeAI, an emerging leader in applying artificial intelligence…
Class Actions Seeks to Represent Untold Number of Caregivers Who Appealed Denials from the VA's…
Fiscal Q1 2026 net revenue of $24.6 million, net income of $0.5 million, operating income…
The digital health market is experiencing robust growth, driven by increasing adoption of telemedicine, wearable…
Strong cash flow, ability to de-lever, and high lender demand drive favorable repricing terms LEHI,…
IRVING, Texas, Aug. 12, 2025 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading,…